In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson’s disease
Open Access
- 22 August 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 27 (22) , 3974-3985
Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by dopaminergic neuron loss. At present, there are no drugs that stop the progression of PD. As with other multifactorial genetic disorders, genome-wide association studies (GWASs) found multiple risk loci for PD, although their clinical significance remains uncertain. Here, we report the identification of candidate drugs for PD by a method using GWAS data and in silico databases. We identified 57 Food and Drug Administration-approved drug families as candidate neuroprotective drugs for PD. Among them, dabrafenib, which is known as a B-Raf kinase inhibitor and is approved for the treatment of malignant melanoma, showed remarkable cytoprotective effects in neurotoxin-treated SH-SY5Y cells and mice. Dabrafenib was found to inhibit apoptosis, and to enhance the phosphorylation of extracellular signal-regulated kinase (ERK), and inhibit the phosphorylation of c-Jun NH2-terminal kinase. Dabrafenib targets B-Raf, and we confirmed a protein–protein interaction between B-Raf and Rit2, which is coded by RIT2, a PD risk gene in Asians and Caucasians. In RIT2-knockout cells, the phosphorylation of ERK was reduced, and dabrafenib treatment improved the ERK phosphorylation. These data indicated that dabrafenib exerts protective effects against neurotoxicity associated with PD. By using animal model, we confirmed the effectiveness of this in silico screening method. Furthermore, our results suggest that this in silico drug screening system is useful in not only neurodegenerative diseases but also other common diseases such as diabetes mellitus and hypertension.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP17ek0109207, JP16ek0109029, JP17ek0410041, JP17km0405206)
- Japan Society for the Promotion of Science (JP17H04056)
- Brain Mapping by Integrated Neurotechnologies for Disease Studies
This publication has 65 references indexed in Scilit:
- Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's diseaseJournal of Neuroscience Research, 2013
- Computational Drug Repositioning: From Data to TherapeuticsClinical Pharmacology & Therapeutics, 2013
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2Annals of Neurology, 2011
- Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin‐induced damageBritish Journal of Pharmacology, 2011
- The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's diseaseLife Sciences, 2011
- Androgens Induce Dopaminergic Neurotoxicity via Caspase-3-Dependent Activation of Protein Kinase CδEndocrinology, 2009
- Signalling molecules essential for neuronal survival and differentiationBiochemical Society Transactions, 2006
- Rin GTPase Couples Nerve Growth Factor Signaling to p38 and b-Raf/ERK Pathways to Promote Neuronal DifferentiationJournal of Biological Chemistry, 2005
- Opposing Effects of ERK and JNK-p38 MAP Kinases on ApoptosisScience, 1995